Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease.
Mesalazine is widely used in the treatment of inflammatory bowel disease. Little is known about the dose-response relationship and about possible dose related side effects. In ulcerative colitis higher dosages of mesalazine (3 g) are more effective in maintaining a remission than lower dosages (1.5...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
1998
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781839/ |